Immune system alterations in lung cancer patients

被引:30
|
作者
Mazzoccoli, G
Grilli, M
Carughi, S
Puzzolante, F
De Cata, A
La Viola, M
Giuliani, A
Urbano, N
Tarquini, R
Perfetto, F
机构
[1] Reg Gen Hosp Casa Sollievo Sofferenza, Dept Internal Med, I-71013 San Giovanni Rotondo, FG, Italy
[2] Reg Gen Hosp Casa Sollievo Sofferenza, Dept Nucl Med, I-71013 San Giovanni Rotondo, FG, Italy
[3] Med Univ Florence, Ctr Chronobiol, Florence, Italy
关键词
circadian rhythm; lymphocyte subpopulations; interleukin; 2; immune response; lung cancer;
D O I
10.1177/039463200301600211
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The immune system plays an important role in the defense against neoplastic disease and immune responses show temporal changes related to circadian variations of antibodies, total lymphocytes in the peripheral blood and cell mediated immune responses. In this study we evaluate. lymphocyte subpopulations and interleukin-2 (IL-2) serum levels in peripheral blood samples collected at four-hour intervals for 24-hours starting at 06.00h from ten healthy subjects aged 65-79 years (mean age +/- S.E. 67.28 +/- 3.11) and from ten subjects suffering from untreated non small cell lung cancer aged 65-78 years (mean age +/- S.E. 68.57 +/- 1.81). Areas under the curve, mean diurnal levels (mean of 06.00-10.00-14.00 h) and mean nocturnal levels (mean of 18.00-22.00-02.00 h) were calculated, and the presence of cireadian rhythmicity was evaluate. When we compared AUC values there was a decrease in CD8(bright) (T suppressor subset) and an increase in CD16 (natural killer cells) and of IL-2 serum levels in cancer patients. When we compared mean diurnal levels, CD8 (T suppressor/cytotoxic subset) and CD8(bright) levels were lower, and CD16 levels were higher in cancer patients. When we compared mean nocturnal levels, CD16 and CD25 (T and B activated lymphocytes with expression of the a chain of IL-2 receptor) levels were higher, while CD8, CD8(bright), CD20 (total B-cells), TcRd1 (epitope of the constant domain of d chain of T-cell receptor 1) and dTcS1 (epitope of the variable domain of d chain of T-cell receptor 1) levels were lower in cancer patients. A clear circadian rhythm was validated for the time-qualified changes in CD4, CD20, HLA-DR with acrophase at night, and CD8, CD8(bright), CD8(dim), CD16, TcRd1 and dTcS1 with acrophase in the morning in the control group. A clear circadian rhythm was validated for the time-qualified changes in CD4 with acrophase at night, in the group of cancer patients. Results obtained in our study show that lung cancer is associated with anomalies of proportion and circadian variations of lymphocyte subsets that must be considered when adoptive immunotherapy has to be planned.
引用
收藏
页码:167 / 174
页数:8
相关论文
共 50 条
  • [31] Biomarkers to predict the efficacy of immune checkpoint inhibitors in patients with nonsmall-cell lung cancer with actionable genetic alterations
    Jun, Soojin
    Jung, Hyun Ae
    Ahn, Myung-Ju
    Ahn, JinSeok
    Lee, Se-Hoon
    Sun, Jong Mu
    Park, Sehhoon
    Cho, Juhee
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [32] Evidence for immune defects in breast and lung cancer patients
    Iuliana Caras
    A. Grigorescu
    Crina Stavaru
    D. L. Radu
    I. Mogos
    G. Szegli
    Aurora Salageanu
    Cancer Immunology, Immunotherapy, 2004, 53 : 1146 - 1152
  • [33] Evidence for immune defects in breast and lung cancer patients
    Caras, I
    Grigorescu, A
    Stavaru, C
    Radu, DL
    Mogos, I
    Szegli, G
    Salageanu, A
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2004, 53 (12) : 1146 - 1152
  • [34] Altered immune response in the transcriptome of patients with lung cancer
    Hijazi, Kahkeshan
    Lel, Julian
    Billatos, Ehab
    Moses, Elizabeth
    Stevenson, Christopher S.
    Lorenzi, Matthew V.
    Liu, Gang
    Campbell, Joshua D.
    Koga, Yusuke
    Zhang, Jiarui
    Duan, Fenghai
    Marques, Helga
    Lenburg, Marc E.
    Spira, Avrum E.
    Beane, Jennifer
    CANCER RESEARCH, 2019, 79 (13)
  • [35] IMMUNE-RESPONSE IN LUNG-CANCER PATIENTS
    MARIN, ND
    KUPIN, VI
    KADAGIDZE, ZG
    VOPROSY ONKOLOGII, 1979, 25 (12) : 72 - 73
  • [36] Characteristics of immune repertoires in early lung cancer patients
    Wang, Jin
    Hu, Xihao
    Zhang, Peng
    Liu, Xiaole Shirley
    CANCER RESEARCH, 2019, 79 (13)
  • [37] Selecting Patients for Immune Checkpoint Inhibition in Lung Cancer
    Garon, Edward B.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (08) : 490 - 492
  • [38] Advances in Immune Checkpoint Inhibition for Patients With Lung Cancer
    Borghaei, Hossein
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (11) : 655 - 657
  • [39] Immune activation and psychological outcome in patients with lung cancer
    Kurz, K.
    Fiegl, M.
    Pircher, M.
    Weiss, G.
    Denz, H. A.
    Holzner, B.
    Fuchs, D.
    JOURNAL OF PSYCHOSOMATIC RESEARCH, 2010, 68 (06) : 640 - 641
  • [40] ASSESSMENT OF IMMUNE DEFENSES IN LUNG-CANCER PATIENTS
    FAGUET, GB
    BEEBE, DP
    JOURNAL OF LEUKOCYTE BIOLOGY, 1984, 36 (03) : 434 - 434